Amgen Entered into a Multi-Year Collaboration Agreement with Tscan Therapeutics to Identify Novel Targets for Crohn's Disease
Shots:
- TScan to receive $30M up front and is eligible to receive ~$500M in success-based preclinical, clinical, regulatory, and commercial milestones along with royalty. Each party will be responsible for its research expenses
- The collaboration combines TScan's proprietary target discovery platform and Amgen's inflammation therapeutic expertise and research capabilities to identify the antigens recognized by T cells in Crohn's disease patients
- Amgen will consider a variety of modalities to develop therapeutics based on targets (identified by TScan) and will continue to hold all global development and commercial rights. Amgen also gets an option to extend the partnership to incl. UC
Ref: PRNewswire | Image: Amgen
Related News:- Amgen Reports Real-World Study Results of Prolia (denosumab) for Osteoporosis Associated with High Fracture Risk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
